Cannabis for Rheumatoid Arthritis: Topical CBD Evidence and Limits

Can topical CBD treat rheumatoid arthritis? The studies discussed here do not establish that CBD creams or cannabis patches prevent joint damage, reverse rheumatoid arthritis (RA), or replace disease-modifying treatment. They offer reasons for further research, with important limits on what patients can conclude.

Editorial update: The Cannabis Community revised this article to clarify the difference between animal research, small human studies, and established RA care. This is an educational research summary, not an individualized treatment recommendation.

What is rheumatoid arthritis?

RA is an autoimmune disease that can damage joints. Treatment has two distinct goals: helping with symptoms and controlling the disease process. Feeling less pain does not, by itself, show that joint damage has stopped.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases emphasizes early treatment and ongoing monitoring. Disease-modifying antirheumatic drugs (DMARDs) are used to slow or change disease progression. Discuss any proposed cannabis product with your rheumatologist; do not stop or reduce prescribed RA treatment on your own.

What the original CBD animal study found

Hammell and colleagues’ rat study, published online in 2015 and in a 2016 journal issue, investigated transdermal CBD in an experimental arthritis model. It reported reductions in inflammation and pain-related behavior.

These were laboratory findings in rats. They do not demonstrate the same benefit in people with RA, establish a dose for patients, or prove that a retail CBD cream can reproduce the experimental formulation’s effects. The study supports further investigation; it is not proof that CBD reverses human joint damage.

What human arthritis studies add

Human research needs to be read by condition, formulation, and study design. Evidence involving osteoarthritis or psoriatic arthritis cannot simply be relabeled as evidence for rheumatoid arthritis.

• A 2022 crossover trial involving 18 people with thumb basal-joint arthritis reported improved pain and disability with topical CBD compared with its control. Its small size, short treatment periods, and different condition limit the conclusions for RA.
• A 2024 open-label study of transdermal CBD for hand osteoarthritis reported improvements during treatment. There was no placebo control, and the authors called for a randomized controlled trial to establish efficacy.
• A 2022 randomized trial of oral CBD in hand osteoarthritis and psoriatic arthritis found no significant pain benefit over placebo. It studied oral CBD, so it does not directly answer whether a particular topical formulation helps.

Together, these studies show why “CBD works for arthritis” is too broad a conclusion. They do not establish a disease-modifying treatment for RA.

Topicals, transdermal products, and wound research

Product names alone do not show how much CBD reaches the tissues or bloodstream. The formulation and the route studied matter. A result from one gel, patch, or oral preparation should not be assumed to apply to every cannabis product.

The 2017 Maida and Corban report discussed three patients with painful pyoderma gangrenosum wounds. Pain relief and reduced opioid use were reported, but this was a small case series about wound pain, not a controlled RA trial. It does not establish that cannabis can replace RA medication.

Safety and opioid claims

NIH’s National Center for Complementary and Integrative Health describes inconsistent evidence about cannabis reducing opioid use. Earlier state-level associations do not prove that cannabis laws caused fewer overdose deaths or that an individual can safely substitute cannabis for prescribed medicine.

CBD and cannabis products can have adverse effects, and CBD can interact with other medicines. Product ingredients and cannabinoid content may also differ from the label. Review the specific product and your full medication list with a clinician or pharmacist.

Questions to take to your rheumatologist

• Is my current treatment controlling inflammation as well as pain?
• Was this product studied in people with RA, or in a different condition?
• Could its ingredients interact with my medicines?
• What symptoms or side effects should prompt me to stop using it and seek advice?
• How will we distinguish symptom relief from changes in disease activity?

If you are exploring state medical-cannabis access, our medical card guide explains the application pathway. A card provides access under a state’s program; it does not establish that a product is effective for RA.

About the original author: Gaurav Dubey holds his Master’s in Biotechnology, and has publications in the field of stem cell research and transplant medicine. Combining his experience as a scientist with his passion for creative writing and medical cannabis, he actively contributes for several clients in the cannabis industry, including: The Medical Cannabis Community, Green Flower Media, Midwest Compassion Care, and Bloom Medicinals.